Literature DB >> 9749370

Molecular modeling of the human vasopressin V2 receptor/agonist complex.

C Czaplewski1, R Kaźmierkiewicz, J Ciarkowski.   

Abstract

The V2 vasopressin renal receptor (V2R), which controls antidiuresis in mammals, is a member of the large family of heptahelical transmembrane (7TM) G protein-coupled receptors (GPCRs). Using the automated GPCR modeling facility available via Internet (http:/(/)expasy.hcuge.ch/swissmod/SWISS-MODEL.+ ++html) for construction of the 7TM domain in accord with the bovine rhodopsin (RD) footprint, and the SYBYL software for addition of the intra- and extracellular domains, the human V2R was modeled. The structure was further refined and its conformational variability tested by the use of a version of the Constrained Simulated Annealing (CSA) protocol developed in this laboratory. An inspection of the resulting structure reveals that the V2R (likewise any GPCR modeled this way) is much thicker and accordingly forms a more spacious TM cavity than most of the hitherto modeled GPCR constructs do, typically based on the structure of bacteriorhodopsin (BRD). Moreover, in this model the 7TM helices are arranged differently than they are in any BRD-based model. Thus, the topology and geometry of the TM cavity, potentially capable of receiving ligands, is in this model quite different than it is in the earlier models. In the subsequent step, two ligands, the native [arginine8]vasopressin (AVP) and the selective agonist [D-arginine8]vasopressin (DAVP) were inserted, each in two topologically non-equivalent ways, into the TM cavity and the resulting structures were equilibrated and their conformational variabilities tested using CSA as above. The best docking was selected and justified upon consideration of ligand-receptor interactions and structure-activity data. Finally, the amino acid residues were indicated, mainly in TM helices 3-7, as potentially important in both AVP and DAVP docking. Among those Cys112, Val115-Lys116, Gln119, Met123 in helix 3; Glu174 in helix 4; Val206, Ala210, Val213-Phe214 in helix 5; Trp284, Phe287-Phe288, Gln291 in helix 6; and Phe307, Leu310, Ala314 and Asn317 in helix 7 appeared to be the most important ones. Many of these residues are invariant for either the GPCR superfamily or the neurophyseal (vasopressin V2R, V1aR and V1bR and oxytocin OR) subfamily of receptors. Moreover, some of the equivalent residues in V1aR have already been found critical for the ligand affinity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749370     DOI: 10.1023/a:1007969526447

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  32 in total

1.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors.

Authors:  S Trumpp-Kallmeyer; J Hoflack; A Bruinvels; M Hibert
Journal:  J Med Chem       Date:  1992-09-18       Impact factor: 7.446

Review 2.  Mutations and diseases of G protein coupled receptors.

Authors:  M Birnbaumer
Journal:  J Recept Signal Transduct Res       Date:  1995 Jan-Mar       Impact factor: 2.092

3.  Predicting antibody hypervariable loop conformations. II: Minimization and molecular dynamics studies of MCPC603 from many randomly generated loop conformations.

Authors:  R M Fine; H Wang; P S Shenkin; D L Yarmush; C Levinthal
Journal:  Proteins       Date:  1986-12

4.  Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy.

Authors:  V M Unger; G F Schertler
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

Review 5.  Structure and function of receptors coupled to G proteins.

Authors:  J M Baldwin
Journal:  Curr Opin Cell Biol       Date:  1994-04       Impact factor: 8.382

6.  Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.

Authors:  A Scheer; F Fanelli; T Costa; P G De Benedetti; S Cotecchia
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

7.  Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy.

Authors:  R Henderson; J M Baldwin; T A Ceska; F Zemlin; E Beckmann; K H Downing
Journal:  J Mol Biol       Date:  1990-06-20       Impact factor: 5.469

8.  Projection structure of rhodopsin.

Authors:  G F Schertler; C Villa; R Henderson
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

9.  Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

Authors:  T Sugimoto; M Saito; S Mochizuki; Y Watanabe; S Hashimoto; H Kawashima
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

10.  The probable arrangement of the helices in G protein-coupled receptors.

Authors:  J M Baldwin
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  9 in total

1.  Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

Authors:  A Giełdoń; R Kaźmierkiewicz; R Slusarz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

2.  Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.

Authors:  Seong W Kang; Srinivas Jayanthi; Gurueswar Nagarajan; Thallapuranam Krishnaswamy Suresh Kumar; Wayne J Kuenzel
Journal:  J Biomol Struct Dyn       Date:  2018-05-17

3.  Conformation and dynamics of 8-Arg-vasopressin in solution.

Authors:  Elke Haensele; Lee Banting; David C Whitley; Timothy Clark
Journal:  J Mol Model       Date:  2014-11-06       Impact factor: 1.810

4.  LigPath: a module for predictive calculation of a ligand's pathway into a receptor-application to the gpH1-receptor.

Authors:  Andrea Strasser; Hans-Joachim Wittmann
Journal:  J Mol Model       Date:  2006-09-20       Impact factor: 1.810

5.  Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Authors:  Sylvia Chen; Matthew J Webber; Jean-Pierre Vilardaga; Ashok Khatri; Dennis Brown; Dennis A Ausiello; Herbert Y Lin; Richard Bouley
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

6.  The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Authors:  Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Int J Oncol       Date:  2015-04-03       Impact factor: 5.650

7.  Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.

Authors:  Juan Garona; Natasha T Sobol; Marina Pifano; Valeria I Segatori; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.679

8.  Modelling the structures of G protein-coupled receptors aided by three-dimensional validation.

Authors:  Siavoush Dastmalchi; W Bret Church; Michael B Morris
Journal:  BMC Bioinformatics       Date:  2008       Impact factor: 3.169

Review 9.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.